Skin Microbiome Peptides in Canada: A Research Guide to LL-37, KPV, Biofilms, Barrier Ecology, and RUO Sourcing

Why the skin microbiome deserves its own peptide guide#

Northern Compound already covers adjacent skin topics: skin barrier peptide research, acne and sebum models, vascular redness and flushing, pruritus and neurogenic inflammation, wound healing, and the LL-37 versus KPV comparison. What was missing was a microbiome-first guide: how should Canadian readers evaluate peptide claims when microbes, host-defence peptides, biofilms, barrier ecology, and inflammatory tone are the primary research variables?

That gap matters because microbiome language is easy to misuse. A compound may reduce growth of one organism in a plate assay and still disrupt a reconstructed epidermis model. A peptide may lower a cytokine after a microbial challenge and still leave the community structure unchanged. A host-defence peptide may be antimicrobial at one concentration, immunomodulatory at another, and cytotoxic or pro-inflammatory in a different matrix. A supplier page may say “antimicrobial” or “skin support,” but the scientific question is narrower: what organism, what strain, what community, what tissue state, what barrier condition, and what endpoint?

Skin is not sterile. It is an active ecosystem shaped by keratinocytes, sebocytes, immune cells, sensory nerves, lipids, sweat, pH, humidity, hair follicles, environmental exposure, and resident microbes. The relevant organisms can include Cutibacterium acnes, Staphylococcus epidermidis, Staphylococcus aureus, Malassezia species, Corynebacterium, fungi, viruses, and strain-level variants within each group. Those organisms can be commensal, opportunistic, inflammatory, protective, or simply present depending on the context.

This guide is written for non-clinical research-use-only evaluation. It does not provide medical advice, infection guidance, dermatology recommendations, topical-use instructions, dosing, compounding details, or personal-use suggestions. Disease terms appear only to describe experimental literature or model features.

The short answer: define the microbial layer before choosing the peptide#

A defensible skin-microbiome peptide project starts by naming the layer of biology under test. “Microbiome support” is not an endpoint. “Antimicrobial activity” is not a complete skin claim. “Reduced inflammation” is not the same as restored ecology.

For the current Northern Compound product map, LL-37 is the most coherent live product reference when the research question involves cathelicidin biology, host-defence peptides, antimicrobial activity, biofilm challenge, keratinocyte signalling, or wound-microbe interactions. KPV is more coherent when the question is inflammatory tone after a microbial or barrier challenge rather than direct microbial killing. GHK-Cu belongs when repair, extracellular matrix, wound-edge remodelling, or post-challenge tissue quality are measured. Melanotan-1 is not a microbiome peptide, but it can be relevant as a cautionary contrast when pigmentation or UV-stress studies risk being overextended into microbiome claims.

The peptide should follow the endpoint. A product link is a documentation checkpoint for an RUO material, not evidence that the material improves human skin ecology.

Skin microbiome biology in one cautious map#

Modern skin-microbiome research describes the skin surface as a set of microenvironments rather than one uniform habitat. Sebaceous areas, moist folds, dry forearms, scalp, hair follicles, wound edges, and inflamed lesions all differ in water availability, lipid content, oxygen exposure, pH, immune tone, and microbial composition. A peptide that behaves one way in a sebaceous follicular model may behave differently on a reconstructed epidermis insert, in an ex vivo wound edge, or in a biofilm matrix.

Reviews of the human skin microbiome emphasise that microbial communities vary by body site and host context (PMID: 28746088). Other reviews describe how host defence, barrier function, and microbial metabolites shape inflammation and repair rather than acting as separate systems (PMID: 26456317). For peptide research, that means the model must state whether the peptide is being tested as a direct antimicrobial, a host-directed signalling molecule, a barrier-modifying tool, or a repair adjunct after microbial stress.

The most important design principle is reciprocity. Microbes can alter host peptide expression, and peptides can alter microbes. Keratinocytes produce antimicrobial peptides such as cathelicidin and beta-defensins after injury, UV exposure, microbial pattern recognition, or inflammatory signalling. Microbes can produce proteases, lipases, short-chain fatty acids, biofilm matrix, and immune triggers. The peptide may be degraded by proteases, bound by matrix components, neutralised by salts, or modified by the local pH. The measured response is therefore the sum of peptide chemistry, microbial state, host-cell state, and the matrix.

That complexity is not a reason to avoid peptide-microbiome research. It is a reason to avoid simple claims. A strong article or protocol says: “In this S. aureus biofilm model with keratinocyte viability and IL-8 endpoints, LL-37 reduced viable counts under these buffer conditions.” A weak article says: “LL-37 balances the skin microbiome.”

LL-37: host-defence peptide, biofilm tool, and interpretation trap#

LL-37 is the active peptide generated from the human cathelicidin precursor hCAP18. It is cationic, amphipathic, membrane-active, and heavily context-dependent. It can disrupt microbial membranes, influence chemotaxis, affect keratinocyte migration, form complexes with nucleic acids, modulate cytokine signalling, and participate in wound and inflammatory responses. Those properties make it central to microbiome-adjacent skin research.

The interpretation trap is that “antimicrobial” sounds simple. It is not. LL-37 activity can change with salt concentration, serum proteins, pH, proteases, glycosaminoglycans, microbial growth phase, biofilm state, and peptide concentration. In one assay, it may reduce planktonic growth. In another, it may be attenuated by matrix material. In a host-cell model, the same concentration range may alter keratinocyte viability or cytokine production.

LL-37 has been studied in antimicrobial and antibiofilm contexts across organisms including S. aureus, P. aeruginosa, and other skin- or wound-relevant microbes. Reviews discuss its broad host-defence role and its vulnerability to degradation or environmental modulation (PMC3699762). Skin disease and wound literature also shows why more LL-37 is not automatically better: cathelicidin processing and LL-37-DNA or LL-37-RNA complexes can amplify inflammation in some contexts, including psoriasis-like and rosacea-like models (PMID: 17502498; PMID: 19769781).

A strong LL-37 microbiome protocol should therefore include at least four controls. First, it should identify the organism or community. S. epidermidis and S. aureus are not interchangeable, and C. acnes strain identity matters. Second, it should separate planktonic and biofilm states. Third, it should measure host-cell compatibility if the claim involves skin rather than a sterile culture tube. Fourth, it should document peptide recovery or stability in the relevant matrix.

Canadian RUO sourcing matters because LL-37 experiments are sensitive to contamination and degradation. Endotoxin or microbial contamination can create inflammatory signals that look like host-defence biology. A degraded lot can change antimicrobial activity. A fill error can shift a concentration-response curve. Before interpreting subtle microbial or cytokine data, readers should look for lot-specific HPLC purity, mass confirmation, fill amount, storage conditions, batch number, and clear research-use-only labelling.

KPV: inflammation around microbial challenge, not a sterilising peptide#

KPV is the Lys-Pro-Val tripeptide sequence associated with alpha-MSH-derived anti-inflammatory signalling. In microbiome research, KPV is not best framed as a direct broad-spectrum antimicrobial. Its stronger role is host-directed: asking whether inflammatory tone around an epithelial, barrier, or microbial challenge changes in a measurable way.

That distinction matters. A microbial model can improve or worsen depending on the balance between host tolerance and host defence. Lower IL-8, TNF-alpha, or NF-kB-associated signalling may reduce inflammatory noise in a keratinocyte model, but it could also mask impaired defensive signalling if microbial burden rises. A KPV experiment should therefore avoid cytokine-only conclusions. If the model includes microbes, it should measure microbial counts or community structure alongside inflammatory endpoints. If it includes barrier damage, it should measure TEWL, differentiation markers, and vehicle controls. If it includes immune cells, it should track recruitment or activation state rather than one isolated cytokine.

KPV is especially useful as a contrast with LL-37. LL-37 can be microbe-facing and host-facing; KPV is more host-response-facing. In an experiment where the question is “does the peptide directly suppress biofilm viability?”, LL-37 is the more coherent test material. In an experiment where the question is “does the host epithelium produce less inflammatory signal after a defined microbial challenge?”, KPV may be more coherent. The best design may include both, but only if the study can separate killing, tolerance, barrier function, and repair.

For Canadian readers, KPV documentation should still be COA-first. A small tripeptide is not automatically simple to interpret. Purity, identity, fill amount, storage, and endotoxin-aware handling matter because inflammatory readouts can be subtle.

GHK-Cu: repair after microbial stress, not microbiome balancing#

GHK-Cu is a copper-binding tripeptide usually discussed around wound repair, extracellular matrix, collagen organisation, angiogenesis-adjacent signalling, and tissue remodelling. It can belong in microbiome-adjacent research when the model includes damaged tissue, wound-edge biology, or post-microbial repair. It is weaker when presented as a direct microbiome-balancing compound.

A GHK-Cu study after microbial challenge should ask repair-specific questions. Does the peptide alter re-epithelialisation after bacterial burden is controlled? Does it change collagen organisation or MMP/TIMP balance at a wound edge? Does it affect angiogenesis markers, fibroblast behaviour, or histology after a biofilm challenge? Does copper state or vehicle composition alter microbial growth independently of the peptide? Those questions are materially different from asking whether a peptide “supports the microbiome.”

The copper context deserves special caution. Copper can influence oxidative chemistry, microbial growth, and host-cell signalling. A protocol that compares GHK-Cu with LL-37 or KPV should not ignore metal state, pH, vehicle, and peptide recovery. A cosmetic-grade or finished topical product is also not the same thing as an RUO lyophilised material; Northern Compound should not treat one as a substitute for the other.

In supplier evaluation, GHK-Cu should be assessed for identity, purity, copper state where available, fill amount, storage, and batch-level documentation. If the model is microbiome-sensitive, contamination and endotoxin context remain important even when the primary endpoint is matrix repair.

Melanotan-1 as a useful boundary case#

Melanotan-1 is included here as a boundary case, not because it is a primary microbiome peptide. It is an alpha-MSH analogue studied around melanocortin signalling, pigmentation, and photoprotection-adjacent research. Those themes can intersect indirectly with skin ecology because UV exposure, pigmentation state, barrier stress, and inflammation can all influence microbial communities. But an indirect intersection is not a microbiome claim.

A Melanotan-1 study should not be described as microbiome research unless it actually measures microbial endpoints. A UV-stress model that tracks pigmentation or oxidative damage may be relevant to photoageing peptide research. It becomes microbiome-adjacent only if it also measures community composition, microbial metabolites, barrier changes, inflammatory response, or colonisation after UV exposure. Otherwise, the microbiome language should be omitted.

This boundary case is useful for compliance. Many skin topics are connected, but Northern Compound should not turn every connection into a product claim. A peptide can be relevant to skin without being relevant to microbiome ecology.

Experimental models: from plate assays to living interfaces#

Microbiome peptide evidence should be ranked by how closely the model matches the claim. A plate assay can answer one question well: does a peptide inhibit or kill a defined organism under defined conditions? It cannot answer whether a peptide improves barrier function, reduces redness, alters community ecology, or supports repair in tissue.

Planktonic assays are useful for screening. They should define organism, strain, medium, pH, ionic strength, inoculum size, growth phase, incubation time, peptide concentration range, and positive controls. Minimum inhibitory concentration and minimum bactericidal concentration are not universal constants; they are assay results.

Biofilm assays add matrix and surface attachment. They should distinguish biomass from viability. Crystal violet staining can show attached material, but live/dead staining, viable counts, confocal microscopy, and matrix analysis provide more interpretive depth. Biofilm models are especially relevant for wounds and follicles, but they can be vulnerable to edge effects, evaporation, surface choice, and media composition.

Keratinocyte or reconstructed epidermis models allow host-response measurement. They can track cytokines, barrier markers, differentiation, viability, and irritancy after microbial or peptide exposure. They still lack full vascular, immune, sebaceous, and neural context unless specifically engineered.

Ex vivo skin and animal models add tissue architecture, immune recruitment, barrier complexity, and wound dynamics. They are more relevant to tissue claims but harder to control. Shaving, anaesthesia, humidity, microbiome baseline, housing, vehicle, and wound method can all influence results.

Community sequencing models can detect shifts in composition, but sequencing data are compositional and not automatically functional. A relative increase in one genus may reflect absolute decline in another. 16S sequencing may not resolve strain-level behaviour. Shotgun metagenomics, metatranscriptomics, metabolomics, and culture can add function, but only if the study is powered and controlled.

The model should match the claim. A strong “LL-37 biofilm” paper does not automatically support a “LL-37 skin microbiome balance” claim. A strong “KPV lowers cytokine output” paper does not automatically support a “KPV controls microbial overgrowth” claim.

Endpoint panels by research question#

A practical way to avoid overclaiming is to build endpoint panels around the question.

If the question is direct antimicrobial activity#

Use organism identity, strain provenance, planktonic growth curves, MIC/MBC, time-kill data, peptide concentration verification, buffer conditions, and a positive antimicrobial control. If the organism is skin-relevant, add host-cell compatibility before making any skin claim. For LL-37, include salt and serum-protein sensitivity where relevant because activity can change in biological matrices.

If the question is biofilm disruption#

Use biofilm biomass, viability, microscopy, extracellular polymeric substance markers, recovery of viable organisms, and time-course design. Include pre-formed biofilm and prevention designs separately. A peptide that prevents attachment may not disrupt an established biofilm. A peptide that disrupts matrix may release inflammatory components. Host-cell and inflammatory endpoints are needed before extrapolating to wounds or follicles.

If the question is inflammatory tolerance#

Use cytokines, NF-kB or TLR markers, inflammasome context, immune-cell behaviour, barrier markers, and microbial burden. KPV fits this layer better than a direct-killing claim. The key is to avoid treating reduced inflammation as automatically good. If microbial burden rises, the interpretation changes.

If the question is barrier ecology#

Use TEWL, tight-junction proteins, cornified-envelope markers, lipid organisation, pH, hydration, microbial challenge, and vehicle controls. A barrier-first model should connect to the skin-barrier peptide guide, not pretend the microbiome can be separated from the physical and chemical surface.

If the question is repair after microbial stress#

Use wound closure, histology, bacterial burden, biofilm state, collagen organisation, angiogenesis markers, inflammatory time course, and peptide recovery. GHK-Cu can be relevant here, but the claim should remain repair-specific. The same protocol may also involve LL-37 when antimicrobial pressure is central.

Supplier and COA checklist for Canadian RUO readers#

Microbiome and inflammatory assays are unusually sensitive to material quality. A peptide lot with acceptable identity but poor handling can still produce misleading results. A trace contaminant can activate TLR pathways. A degraded peptide can lose antimicrobial activity. A mislabeled fill can turn a sub-toxic concentration into a cytotoxic one. A product page that lacks batch context cannot support a subtle endpoint claim.

Before interpreting a skin-microbiome peptide result, Canadian readers should look for:

• lot-specific HPLC purity rather than generic purity claims;
• mass confirmation or another appropriate identity method;
• fill amount and batch number that match the vial;
• storage requirements and cold-chain expectations;
• clear research-use-only labelling and no human-use or treatment positioning;
• endotoxin or microbial-contamination context when inflammatory, immune, or barrier endpoints are central;
• peptide stability or recovery data when the model includes serum, wound fluid, proteases, biofilm matrix, topical vehicles, or ex vivo tissue;
• pH, osmolarity, solvent, and vehicle controls for skin-contact experiments;
• current product destinations that do not 404 and preserve Northern Compound attribution.

LL-37, KPV, GHK-Cu, and Melanotan-1 should be evaluated through that documentation lens. The link is not an endorsement of personal use; it is a route to inspect current supplier information for research-use-only materials.

How this guide fits the Northern Compound skin archive#

This guide fills a skin-category gap between barrier biology, acne/sebum research, redness, wound healing, and compound-level pages. The skin-barrier guide asks how epithelial integrity, lipids, and antimicrobial defence hold the interface together. The acne guide focuses on follicles, sebum, C. acnes, and inflammatory lesions. The vascular redness guide asks whether colour changes are vascular, immune, neurogenic, or barrier-driven. The wound-healing guide asks how repair proceeds after injury.

The unique role of this page is ecological interpretation. It asks whether a peptide claim is about killing, tolerance, barrier state, community composition, biofilm architecture, or repair after microbial stress. That distinction keeps the archive scientifically cleaner and commercially safer. It also helps readers avoid product-selection shortcuts: a peptide can be relevant to one skin-microbe question and irrelevant to another.

Evidence-quality ladder for skin-microbiome peptide claims#

Not all evidence carries the same weight.

Lowest weight: broad supplier language. Terms such as “microbiome support,” “skin defence,” “calming,” or “balances bacteria” are not endpoints. They may suggest a hypothesis, but they do not establish one.

Low weight: single-organism plate assays. These can be useful, especially for LL-37, but they are narrow. They depend on strain, medium, pH, salt, growth phase, and concentration. They should not be translated into human skin claims.

Moderate weight: biofilm assays with viability and microscopy. These are stronger for wound or follicular hypotheses, but still need host-cell and inflammatory context before tissue claims are made.

Moderate to higher weight: host-cell or reconstructed epidermis models with microbial challenge. These can connect microbes to keratinocyte signalling, barrier markers, viability, and irritancy. They remain limited if they lack sebaceous, vascular, neural, or immune-cell context.

Higher weight: ex vivo or animal models with microbial, barrier, inflammatory, and repair endpoints. These models better approximate tissue interactions but are harder to control. They need baseline microbiome documentation, environmental controls, and material-quality data.

Highest practical weight: replicated, endpoint-matched studies across lots and models. A single result is fragile. Replication across peptide lots, organisms, host models, and analytical methods is what turns a plausible peptide-microbiome claim into more reliable research evidence.

Organism-specific cautions: do not treat the microbiome as one target#

A useful microbiome article should name organisms without turning them into villains. The same organism can be harmless, helpful, inflammatory, or opportunistic depending on body site, strain, abundance, host state, and model conditions.

Cutibacterium acnes is the obvious example because acne research often turns it into a single pathogen. In reality, C. acnes is common on healthy skin and includes strain-level variation. A follicular model should state whether the organism is planktonic or biofilm-associated, whether sebum-like lipids are present, whether oxygen exposure is realistic, and whether keratinocyte or sebocyte inflammatory responses are measured. LL-37 can be relevant to antimicrobial or inflammatory questions, but killing one C. acnes strain in a plate does not prove a beneficial effect in follicular ecology.

Staphylococcus epidermidis is often treated as a friendly commensal, but that is still too simple. Some S. epidermidis strains can produce antimicrobial factors that compete with pathogens; other contexts can involve biofilm formation or opportunistic behaviour on disrupted barriers and implanted materials. If a peptide reduces S. epidermidis abundance, the result is not automatically good or bad. The study should ask what function changed: colonisation resistance, inflammatory signalling, barrier markers, or biofilm state.

Staphylococcus aureus is more often associated with inflammatory and barrier-disrupted models, including atopic-dermatitis-like contexts. It can form biofilms, produce toxins, and amplify inflammation. LL-37 may be relevant in S. aureus challenge models, but the same caveats apply: ionic strength, proteases, biofilm matrix, cytotoxicity, and host-cell response all shape interpretation. A peptide that lowers viable counts while injuring keratinocytes is not an uncomplicated win.

Malassezia and other fungi create another layer. Fungal organisms interact with lipids, sebaceous regions, barrier state, and host immunity in ways that bacterial-only sequencing can miss. If a study uses only 16S sequencing, it may not see fungal dynamics. A microbiome peptide article that discusses scalp, sebaceous skin, or dermatitis-like models should ask whether fungal endpoints or internal transcribed spacer sequencing are relevant.

Mixed communities are the highest bar. In a mixed community, a peptide may suppress one organism, free another from competition, alter metabolites, change pH, or affect host cells indirectly. Relative-abundance data can be misleading because one organism's apparent rise may reflect another organism's decline. Stronger studies combine sequencing with absolute quantification, culture, host endpoints, and functional readouts.

Topical and matrix variables that can overwhelm the peptide signal#

Many skin-microbiome experiments fail because the vehicle or matrix is treated as neutral. It rarely is. Solvents, pH adjusters, preservatives, salts, surfactants, viscosity agents, and metal ions can all alter microbial growth and barrier response. A peptide dissolved in one buffer cannot be compared casually with another peptide dissolved in a different vehicle.

Topical and ex vivo systems also introduce recovery problems. A peptide may bind plastic, skin lipids, extracellular matrix, wound exudate, bacterial biofilm, serum proteins, or glycosaminoglycans. It may be degraded by host proteases or microbial proteases. It may aggregate at higher concentration or lose activity in high-salt conditions. Without recovery data, the researcher may not know whether a negative result reflects biology or disappearance of the test material.

For GHK-Cu, copper coordination, oxidation, and pH deserve special attention. For LL-37, cationic charge and amphipathic structure make buffer and matrix effects especially important. For KPV, small-peptide stability and concentration verification still matter because inflammatory endpoints may shift subtly. The stronger the claim, the more the protocol must show that the peptide actually remained present and interpretable in the model.

This is one reason Northern Compound avoids cosmetic formulation language in RUO articles. A lyophilised research material is not a finished topical product. A vehicle used for an in vitro assay is not a personal-use preparation. A stability result in a buffered research model does not establish performance in a consumer formulation.

How to compare LL-37, KPV, and GHK-Cu without ranking them#

Readers often want a simple answer: which peptide is best for the skin microbiome? That question is less useful than an endpoint-matched comparison.

Choose an LL-37-centred hypothesis when the model explicitly involves host-defence peptide biology, direct antimicrobial exposure, biofilm challenge, cathelicidin signalling, keratinocyte activation, or wound-microbe interactions. The primary controls are organism identity, concentration-response, cytotoxicity, ionic strength, protease sensitivity, and host inflammatory response.

Choose a KPV-centred hypothesis when the model asks how epithelial or immune cells respond to a defined challenge. The primary controls are microbial burden, cytokines, barrier state, and whether lower inflammation compromises or preserves defence. KPV is weaker when the endpoint is direct microbial killing.

Choose a GHK-Cu-centred hypothesis when the model asks how tissue repairs after microbial or barrier stress. The primary controls are matrix remodelling, wound closure, histology, copper state, vehicle compatibility, and whether microbial pressure has already been controlled. GHK-Cu is weaker when the endpoint is community composition alone.

That endpoint-first approach prevents over-ranking. A peptide can be the right tool for one microbiome-adjacent experiment and the wrong tool for another. It also keeps commercial linking honest: LL-37, KPV, and GHK-Cu are not interchangeable catalogue entries; they are research materials that require different endpoint panels.

Language Northern Compound avoids on this topic#

Northern Compound should avoid language that implies personal-use microbiome manipulation or treatment. Weak phrases include “restores the skin microbiome,” “treats bacterial acne,” “kills bad bacteria while preserving good bacteria,” “heals infected wounds,” “prevents infection,” “calms rosacea,” “repairs the skin flora,” or “balances skin bacteria.” Those phrases can imply therapeutic or cosmetic outcomes that an RUO editorial site should not claim.

Stronger language is narrower: “LL-37 is relevant to host-defence and biofilm research models,” “KPV may be useful in inflammatory-tone hypotheses where microbial burden is also measured,” “GHK-Cu belongs in repair-focused models after microbial stress,” or “microbiome claims require organism identity, community data, barrier endpoints, and lot-specific peptide documentation.”

That language is better for readers and safer for compliance. It tells Canadian researchers what to measure without pretending that supplier access equals a human-use recommendation.

Practical due-diligence questions before following a product link#

Before using a product link to inspect supplier documentation, ask:

1. Is the research question direct antimicrobial activity, biofilm behaviour, inflammatory tolerance, barrier ecology, repair, or pigmentation/UV context?
2. Does the peptide match that question, or is it being chosen because it is popular in skin forums?
3. Are the organisms and strains defined?
4. Are planktonic and biofilm states separated?
5. Are host-cell viability and inflammatory endpoints measured?
6. Are barrier markers and vehicle controls included?
7. Is peptide stability or recovery checked in the relevant matrix?
8. Is endotoxin or microbial contamination considered?
9. Does the supplier provide lot-specific HPLC, mass confirmation, fill amount, batch number, and storage conditions?
10. Does the article avoid dosing, treatment, cosmetic, or personal-use instructions?

If the answer to several of those questions is no, the claim should be narrowed before a product page drives decision-making.

Bottom line for Canadian researchers#

Skin microbiome peptide research is strongest when it refuses shortcuts. The skin surface is an ecosystem, not a sterile target. LL-37, KPV, GHK-Cu, and boundary-case skin peptides can all be relevant to carefully framed experiments, but they answer different questions. LL-37 belongs closest to host-defence and biofilm models. KPV belongs closest to inflammatory tolerance. GHK-Cu belongs closest to repair after stress. Melanotan-1 is useful mainly as a reminder that not every skin peptide is a microbiome peptide.

For Canadian readers, the practical standard is simple: define the endpoint, match the peptide to the endpoint, demand batch-level documentation, verify the product destination, and keep the language research-use-only. Anything broader risks turning microbiome science into marketing shorthand.